microarray peptide assay (PamGene International B.V)
Structured Review

Microarray Peptide Assay, supplied by PamGene International B.V, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/peptide+microarray/pamchip+peptide+microarrays/pmc11655848-57-22-22
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer"
Article Title: Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer
Journal: Cell Death & Disease
doi: 10.1038/s41419-024-07272-7
Figure Legend Snippet: A Schematic model showing the PTK PamChip peptide microarray system and experimental design. B Heat map of up-and down-regulated Tyrosine (PTK assay) bait peptide phosphorylation of lorlatinib (4 h) versus DMSO treatment by peptide chip array ( n = 3 biological replicates) in H3122 and H2228 cell lines. Significant peptides ( p < 0.05) were clustered using hierarchical order and Euclidean/ward algorithm. C , D Volcano plots of the bait peptide phosphorylation from PTK chip arrays in A showing significant up- (Red) and downregulation (blue) of peptide phosphorylation as defined by ANOVA and post-hoc Dunnett’s test versus DMSO treatment ( p < 0.05). Non-significant peptides were highlighted in grey. Downregulated peptides were highlighted in light blue. ERBB family and AKT1 phosphopeptides were highlighted in green and black bold colours, respectively. E Venn diagram was generated to compare the phosphorylated Tyr peptides (up- and downregulated) after a 4 h treatment with lorlatinib in H3122 and H2228 cell lines. Tables of the specific phosphorylated Tyr sites and the associated proteins are shown. The down-regulated proteins were highlighted in cyan colour. The upregulated proteins selected for further analysis were highlighted in bold with green and black colours.
Techniques Used: Peptide Microarray, Generated
Related Articles
Phospho-proteomics:Article Title: Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer Article Snippet: .. To identify adaptive response mechanisms, we examined the landscape of tyrosine phosphorylation upon acute LOR treatment in EML4-ALK-positive NSCLC cell lines using Article Title: Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK non-small cell lung cancer Article Snippet: .. Results Kinase activity pro ling revealed increased Tyrosine phosphorylation after lorlatinib treatment To identify adaptive response mechanisms, we examined the landscape of tyrosine phosphorylation upon acute lorlatnib treatment in EML4-ALK-positive NSCLC cell lines using Microarray:Article Title: Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer Article Snippet: .. To identify adaptive response mechanisms, we examined the landscape of tyrosine phosphorylation upon acute LOR treatment in EML4-ALK-positive NSCLC cell lines using Article Title: Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK non-small cell lung cancer Article Snippet: .. Results Kinase activity pro ling revealed increased Tyrosine phosphorylation after lorlatinib treatment To identify adaptive response mechanisms, we examined the landscape of tyrosine phosphorylation upon acute lorlatnib treatment in EML4-ALK-positive NSCLC cell lines using other:Article Title: Kinome and mRNA expression profiling of high-grade osteosarcoma cell lines implies Akt signaling as possible target for therapy Article Snippet: Kinome profiling was performed on 1 μg of Article Title: Exploring antiproliferative activities and kinase profile of ortho-substituted N-(4-(2-(benzylamino)-2-oxoethyl)phenyl)benzamides. Article Snippet: Yosra A. Muhammad and Abdelsattar M. Omar contributed equally to this work.. 1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia 2Centre for Artificial Intelligence in Precision Medicines, King Abdulaziz University, Jeddah, Saudi Arabia 3Department of Pharmaceutical Chemistry, Faculty of Pharmacy, AlAzhar University, Cairo, Egypt 4Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia 5Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia 6Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia 7Department of Natural Products, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia Article Title: Phosphocatalytic Kinome Activity Profiling of Apoptotic and Ferroptotic Agents in Multiple Myeloma Cells Article Snippet: Tyrosine and serine-/threonine kinase profiles were determined by employing the Article Title: ARID1A-induced transcriptional reprogramming rewires signalling responses to drug treatment in melanoma Article Snippet: Protein Tyrosine Kinase (PTK) and Serine/Threonine Kinase (STK) activity profiles were assessed using Analysis:Article Title: Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma Article Snippet: 30 Kinome analysis For kinomic profiling, HMCLs were lysed in M-PER mammalian protein extraction reagent (Thermo Fisher Scientific) containing Halt protease and Halt phosphatase inhibitor cocktails (Thermo Fisher Scientific). .. Analysis of serine/threonine kinase (STK) activity was performed by using the Activity Assay:Article Title: Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma Article Snippet: 30 Kinome analysis For kinomic profiling, HMCLs were lysed in M-PER mammalian protein extraction reagent (Thermo Fisher Scientific) containing Halt protease and Halt phosphatase inhibitor cocktails (Thermo Fisher Scientific). .. Analysis of serine/threonine kinase (STK) activity was performed by using the Article Title: Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma. Article Snippet: Background: Histone deacetylase inhibitors (HDACi) are used to treat patients with cutaneous T-cell lymphoma (CTCL), but they show limited efficacy.. Hence, combination therapies should be explored to enhance the effectiveness of HDACis.. Objective: This study was conducted to identify novel therapeutic targets that can be combined with HDACis for treating CTCL. Article Title: Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK non-small cell lung cancer Article Snippet: .. Results Kinase activity pro ling revealed increased Tyrosine phosphorylation after lorlatinib treatment To identify adaptive response mechanisms, we examined the landscape of tyrosine phosphorylation upon acute lorlatnib treatment in EML4-ALK-positive NSCLC cell lines using Peptide Microarray:Article Title: Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma Article Snippet: 30 Kinome analysis For kinomic profiling, HMCLs were lysed in M-PER mammalian protein extraction reagent (Thermo Fisher Scientific) containing Halt protease and Halt phosphatase inhibitor cocktails (Thermo Fisher Scientific). .. Analysis of serine/threonine kinase (STK) activity was performed by using the Article Title: Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma. Article Snippet: Background: Histone deacetylase inhibitors (HDACi) are used to treat patients with cutaneous T-cell lymphoma (CTCL), but they show limited efficacy.. Hence, combination therapies should be explored to enhance the effectiveness of HDACis.. Objective: This study was conducted to identify novel therapeutic targets that can be combined with HDACis for treating CTCL. |
